Joseph Hsieh

Take a deep breath. You’ve got 3 months and a few weeks until the big holiday weekend. It’ll be a lot of work—and somewhat hectic—no matter what. But there’s plenty you can get done this month to set your brand up for success. In the last 7 years at Retention Commerce, I’ve worked with dozens of brands both big and small on their email and SMS strategy going into BFCM. Regardless of their size, planning for BFCM is always a high stress moment.

If you’re like most marketers, you have the basics of A/B testing down to a science. You develop a hypothesis about your tactic, decide which metric will determine a winner, choose your variable to test, and set the test live. Brands can gain a lot from traditional A/B testing, but once you’ve built a bigger audience, you can do more advanced kinds of testing.

Abstract Rhabdomyosarcoma (RMS), a malignancy of impaired myogenic differentiation, is the most common soft tissue pediatric cancer. PAX3-FOXO1 oncofusions drive the majority of the clinically more aggressive fusion-positive rhabdomyosarcoma (FP-RMS). Recent studies have established an epigenetic basis for PAX3-FOXO1-driven oncogenic processes.